EP1458758A2 - Fragments et conjugues de l'adiponectine - Google Patents

Fragments et conjugues de l'adiponectine

Info

Publication number
EP1458758A2
EP1458758A2 EP02792711A EP02792711A EP1458758A2 EP 1458758 A2 EP1458758 A2 EP 1458758A2 EP 02792711 A EP02792711 A EP 02792711A EP 02792711 A EP02792711 A EP 02792711A EP 1458758 A2 EP1458758 A2 EP 1458758A2
Authority
EP
European Patent Office
Prior art keywords
adiponectin polypeptide
seq
adiponectin
polypeptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02792711A
Other languages
German (de)
English (en)
Inventor
Poul Baad Rasmussen
Kim Vilbour Andersen
Anders Hjelholt Pedersen
Hans Thalsgaard Schambye
Torben Halkier
Are Bogsnes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxygen ApS
Maxygen Holdings Ltd
Original Assignee
Maxygen ApS
Maxygen Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen ApS, Maxygen Holdings Ltd filed Critical Maxygen ApS
Publication of EP1458758A2 publication Critical patent/EP1458758A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

L'invention concerne un conjugué comprenant un polypeptide de l'adiponectine, et une première fraction non polypeptidique liée de manière covalente au polypeptide de l'adiponectine. Le polypeptide de l'adiponectine comprend un résidu d'amino-acide ayant un groupe de fixation pour la première fraction non polypeptidique. Ledit résidu d'amino-acide a été introduit dans une position qui, dans l'adiponectine parent, est occupée par un résidu d'amino-acide exposé en surface.
EP02792711A 2001-12-21 2002-12-20 Fragments et conjugues de l'adiponectine Withdrawn EP1458758A2 (fr)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US34348201P 2001-12-21 2001-12-21
DKPA200101952 2001-12-21
DK200101952 2001-12-21
US37549202P 2002-04-25 2002-04-25
DKPA200200627 2002-04-25
US375492P 2002-04-25
DK200200627 2002-04-25
US39411702P 2002-07-03 2002-07-03
DK200201036 2002-07-03
DKPA200201036 2002-07-03
US394117P 2002-07-03
US41216902P 2002-09-20 2002-09-20
DKPA200201385 2002-09-20
US412169P 2002-09-20
DK200201385 2002-09-20
PCT/DK2002/000897 WO2003055916A2 (fr) 2001-12-21 2002-12-20 Fragments et conjugues de l'adiponectine
US343482P 2010-04-29

Publications (1)

Publication Number Publication Date
EP1458758A2 true EP1458758A2 (fr) 2004-09-22

Family

ID=27570813

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02792711A Withdrawn EP1458758A2 (fr) 2001-12-21 2002-12-20 Fragments et conjugues de l'adiponectine

Country Status (5)

Country Link
EP (1) EP1458758A2 (fr)
JP (1) JP2005526492A (fr)
AU (1) AU2002358467A1 (fr)
CA (1) CA2468619A1 (fr)
WO (1) WO2003055916A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1886423A (zh) 2002-01-18 2006-12-27 普罗特米克斯公司 脂联素的糖基同工型及其用途
WO2003097689A1 (fr) * 2002-05-17 2003-11-27 Serono Genetics Institute S.A. Fragments d'obg3 inhibant la conversion d'obg3 actif en obg3 de plus faible activite et autres compositions pour le traitement de troubles metaboliques
EP1509545B8 (fr) * 2002-05-31 2010-10-13 Merck Serono Biodevelopment SAS Tete globulaire de obg3 etendue et homotrimere et utilisations associees
US7176292B2 (en) * 2003-09-11 2007-02-13 Dialean, Ltd. Ghrelin variant protein
ATE515699T1 (de) * 2004-03-31 2011-07-15 Kazuhisa Maeda Verwendung von adiponectin als marker in der vorhersage post-operativer infektion
WO2006061853A2 (fr) * 2004-12-10 2006-06-15 Serum Institute Of India Limited Nouveaux composes erythropoietiques et leur procede de production
US7749956B2 (en) 2005-01-07 2010-07-06 Xencor, Inc. Method of treatment using adiponectin variants
US7592423B2 (en) 2005-01-07 2009-09-22 Xencor, Inc. Globular adiponectin variants
JP2008526885A (ja) * 2005-01-07 2008-07-24 ゼンコア アディポネクチン変異体
US7964557B2 (en) 2005-03-28 2011-06-21 University Of Louisville Research Foundation, Inc. Inhibition of wet type age related macular degeneration (AMD) by adiponectin or acrp 30
CN1740195B (zh) * 2005-04-15 2012-01-04 复旦大学 一种多肽gapM1及其制备方法
US7709607B2 (en) 2005-07-11 2010-05-04 Xencor, Inc. Adiponectin variants
WO2007008937A2 (fr) * 2005-07-11 2007-01-18 Xencor Variants d'adiponectine
US20090291091A1 (en) * 2005-07-29 2009-11-26 Laboratoires Serono Sa Use of the globular domain of acrp30 for the preparation of a medicament for the prevention and/or treatment of thrombosis-related diseases
CN101415461A (zh) * 2006-01-09 2009-04-22 儿童医院医疗中心 用于治疗各种疾病的脂连蛋白
WO2008067599A1 (fr) * 2006-12-04 2008-06-12 Apollo Life Sciences Limited Molécules isolées de leptine et d'adiponectine et molécules chimériques de celles-ci
US8026345B2 (en) * 2007-01-08 2011-09-27 Hoffmann-La Roche Inc. Characterization and identification of unique human adiponectin isoforms and antibodies
US9913880B2 (en) * 2011-02-18 2018-03-13 Stemdr Inc. Method of treating sepsis or septic shock
CN104004066B (zh) * 2013-02-26 2017-05-31 上海市第一人民医院 预防或抑制炎症反应和血管新生的小分子多肽及其应用
WO2018004067A1 (fr) * 2016-07-01 2018-01-04 전남대학교 산학협력단 Lignée cellulaire de surexpression d'adiponectine
CN112209995B (zh) * 2020-10-14 2022-01-11 华兰基因工程有限公司 一种SARS-CoV-2表面蛋白受体结合区制备方法
CN112521481B (zh) * 2020-12-08 2022-11-04 武汉市工程科学技术研究院 表面修饰物及其制备方法和应用
CN112574306B (zh) * 2020-12-17 2023-05-05 武汉华美生物工程有限公司 脂联素单克隆抗体、抗体对及其制备方法和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74177A (en) * 1984-02-03 1989-09-10 Abbott Lab Stabilized enzyme conjugate composition containing a calcium salt and a polyethylene glycol
ATE405655T1 (de) * 2000-01-14 2008-09-15 Serono Genetics Inst Sa Obg3 globularekopf und seine verwendungen zur reduzierung des körpersgewichtes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03055916A2 *

Also Published As

Publication number Publication date
CA2468619A1 (fr) 2003-07-10
JP2005526492A (ja) 2005-09-08
WO2003055916A2 (fr) 2003-07-10
WO2003055916A3 (fr) 2003-12-31
AU2002358467A1 (en) 2003-07-15

Similar Documents

Publication Publication Date Title
US7232562B2 (en) E38N interferon gamma polypeptide variants
WO2003055916A2 (fr) Fragments et conjugues de l'adiponectine
US7419805B2 (en) Polynucleotides encoding S99T interferon gamma polypeptide variants and means of expression
WO2002074806A2 (fr) Nouvelles molecules de type interferon beta
US20060052292A1 (en) Adiponectin fragments and conjugates
US20030186386A1 (en) Interleukin 10
US7390638B2 (en) S99T C-11 Truncated polynucleotides encoding interferon gamma polypeptide variants
JP2004524020A (ja) 改良された成長ホルモン分子
EP1257574A1 (fr) Interleukine-10 amelioree
US7230081B1 (en) Interferon gamma conjugates
NZ528651A (en) Glycosylated interferon gamma polypeptide variants
US7524931B2 (en) Full-length interferon gamma polypeptide variants
AU2002252971B2 (en) Interferon gamma polypeptide variants
AU782635B2 (en) Interferon gamma conjugates
ZA200308376B (en) Interferon gamma polypeptide variants.
AU2002252971A1 (en) Interferon gamma polypeptide variants
CZ20033016A3 (cs) Varianty polpeptidu interferonu gamma
AU2002235727A1 (en) New interferon beta-like molecules

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040721

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070703